Marinus Pharmaceuticals Earnings Reports

Marinus Pharmaceuticals reported Q3 2024 net product revenue of $8.5 million, a 56% increase compared to Q3 2023. The company is narrowing its full-year 2024 ZTALMY net product revenue guidance to $33 to $34 million. Marinus has commenced a process to explore strategic alternatives and implemented cost reduction plans, with cash runway expected into Q2 2025.

Marinus Pharmaceuticals reported an 87% increase in ZTALMY net product revenue for Q2 2024 compared to Q2 2023, reaching $8.0 million. The company is on track to meet its full-year revenue guidance for ZTALMY. Enrollment was completed in the Phase 3 TrustTSC trial, with topline data expected in Q4 2024.

Marinus Pharmaceuticals reported Q1 2024 net product revenue of $7.5 million, a 125% increase compared to Q1 2023. The company has implemented cost reduction plans to extend the cash runway into late Q1 2025. They are also preparing for topline results from the Phase 3 RAISE trial expected early summer 2024.

Marinus Pharmaceuticals reported ZTALMY net product revenue of $6.6 million for Q4 2023 and expects full year 2024 U.S. ZTALMY net product revenues of between $32 and $34 million. The company's cash runway is projected into Q4 2024, with cash, cash equivalents, and short-term investments of $150.3 million as of December 31, 2023.

Marinus Pharmaceuticals reported its Q3 2023 financial results, highlighting a ZTALMY net product revenue of $5.4 million. The company increased its full year 2023 expected ZTALMY net product revenues to between $18.5 and $19 million. The company's cash runway is projected into Q4 2024, with cash, cash equivalents, and short-term investments of $176.4 million as of September 30, 2023.

Marinus Pharmaceuticals reported its second-quarter financial results, featuring a net product revenue of $4.2 million from ZTALMY. The company increased its full-year 2023 net product revenue guidance to between $17 and $18.5 million. The European Commission approved ZTALMY in CDKL5 deficiency disorder. The company's cash runway is expected into the second half of 2024, with $175.3 million in cash, cash equivalents, and short-term investments as of June 30, 2023.

Marinus Pharmaceuticals reported ZTALMY U.S. net product revenue of $3.3 million for the first quarter of 2023. The company is on track to meet its full year revenue guidance of $15-17 million. They are planning an interim analysis for the Phase 3 refractory status epilepticus trial in the second half of 2023.

Marinus Pharmaceuticals reported Q4 2022 financial results, featuring $2.3 million in ZTALMY U.S. net product revenue and $3.0 million in collaboration revenue. The company's cash and cash equivalents stood at $240.6 million as of December 31, 2022, expected to fund operations into the second half of 2024.

Marinus Pharmaceuticals reported Q3 2022 financial results, marked by the U.S. commercial launch of ZTALMY which generated $0.56 million in net product revenue. Strategic financial decisions, including the sale of a Priority Review Voucher and a revenue interest financing agreement, are expected to extend the company's cash runway into Q1 2024.

Marinus Pharmaceuticals reported financial results for the second quarter ended June 30, 2022. The company continued to prepare for the commercial launch of ZTALMY and progressed its Phase 3 TrustTSC and RAISE trials.

Marinus Pharmaceuticals reported its Q1 2022 financial results, highlighting progress in their clinical programs and preparation for the first commercial launch. The company is on track with the Phase 3 RAISE trial in refractory status epilepticus and is developing next-generation formulations for new indications like Lennox-Gastaut syndrome.

Marinus Pharmaceuticals announced the FDA approval of ZTALMY® for CDKL5 deficiency disorder and reported financial results for Q4 and full year 2021. The company is focused on expanding the clinical development of ganaxolone across various seizure disorders and preparing for commercialization.

Marinus Pharmaceuticals reported steady progress across its clinical programs and commercialization planning efforts in Q3 2021. The company aims to have ganaxolone commercially available in the U.S. and Europe by mid-2022, pending regulatory approvals.

Marinus Pharmaceuticals reported its Q2 2021 financial results and provided an update on its clinical and regulatory development activities. Key highlights include the European collaboration with Orion Corporation and the submission of the NDA for ganaxolone in CDKL5 deficiency disorder.

Marinus Pharmaceuticals announced an agreement with Oaktree for up to $125 million in credit financing to support commercial, clinical, and next-generation formulations. The company is progressing with clinical programs and targeting NDA submission for ganaxolone in CDKL5 deficiency disorder by mid-2021.

Marinus Pharmaceuticals reported a net loss of $17.5 million for the fourth quarter of 2020, with research and development expenses increasing to $13.0 million and general and administrative expenses increasing to $6 million. The company ended the year with $140.0 million in cash, cash equivalents and investments.

Marinus Pharmaceuticals reported positive results from the Marigold Study and progress in its status epilepticus program. The company had cash, cash equivalents and investments of $91.3 million as of September 30, 2020, which is expected to fund operations into 2022.

Marinus Pharmaceuticals reported a net loss of $15.7 million for the second quarter of 2020, with research and development expenses increasing to $11.8 million. The company's cash, cash equivalents, and investments totaled $105.9 million as of June 30, 2020.

Marinus Pharmaceuticals reported a net loss of $18.7 million for the first quarter of 2020, compared to a net loss of $12.5 million for the same period in 2019. The company's cash and cash equivalents totaled $77.8 million as of March 31, 2020.

Marinus Pharmaceuticals reported its financial results for the year ended December 31, 2019, with a net loss of $54.1 million. The company's cash and cash equivalents were $90.9 million as of December 31, 2019, expected to fund operations into the third quarter of 2021.